These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20618329)

  • 41. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E; Okada CY
    J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system.
    Rhee Fv
    Clin Cancer Res; 2007 Mar; 13(5):1353-5. PubMed ID: 17332275
    [No Abstract]   [Full Text] [Related]  

  • 43. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
    Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
    J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients.
    Abdalla AO; Hansson L; Eriksson I; Näsman-Glaser B; Mellstedt H; Osterborg A
    Eur J Haematol; 2007 Nov; 79(5):371-81. PubMed ID: 17916084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
    Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
    Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
    Davis TA; Hsu FJ; Caspar CB; van Beckhoven A; Czerwinsk DK; Liles TM; Taidi B; Benike CJ; Engleman EG; Levy R
    Biol Blood Marrow Transplant; 2001; 7(9):517-22. PubMed ID: 11669219
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival.
    Barth RJ; Fisher DA; Wallace PK; Channon JY; Noelle RJ; Gui J; Ernstoff MS
    Clin Cancer Res; 2010 Nov; 16(22):5548-56. PubMed ID: 20884622
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma.
    Himoudi N; Wallace R; Parsley KL; Gilmour K; Barrie AU; Howe K; Dong R; Sebire NJ; Michalski A; Thrasher AJ; Anderson J
    Clin Transl Oncol; 2012 Apr; 14(4):271-9. PubMed ID: 22484634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
    Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
    Clin Cancer Res; 2007 Mar; 13(5):1503-10. PubMed ID: 17332295
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.
    Höltl L; Ramoner R; Zelle-Rieser C; Gander H; Putz T; Papesh C; Nussbaumer W; Falkensammer C; Bartsch G; Thurnher M
    Cancer Immunol Immunother; 2005 Jul; 54(7):663-70. PubMed ID: 15918076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
    Kwak LW; Young HA; Pennington RW; Weeks SD
    Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dendritic cell KLH loading requirements for efficient CD4+ T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines.
    Millard AL; Ittelet D; Schooneman F; Bernard J
    Vaccine; 2003 Feb; 21(9-10):869-76. PubMed ID: 12547596
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells.
    Kim SB; Baskar S; Kwak LW
    Leuk Lymphoma; 2003 Jul; 44(7):1201-8. PubMed ID: 12916873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.
    Kafi K; Betting DJ; Yamada RE; Bacica M; Steward KK; Timmerman JM
    Mol Immunol; 2009 Jan; 46(3):448-56. PubMed ID: 19046770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model.
    Stritzke J; Zunkel T; Steinmann J; Schmitz N; Uharek L; Zeis M
    Br J Haematol; 2003 Jan; 120(1):27-35. PubMed ID: 12492573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
    Nestle FO; Alijagic S; Gilliet M; Sun Y; Grabbe S; Dummer R; Burg G; Schadendorf D
    Nat Med; 1998 Mar; 4(3):328-32. PubMed ID: 9500607
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma.
    Hollander N
    Crit Rev Immunol; 2009; 29(5):399-418. PubMed ID: 20001888
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
    Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P
    Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.